NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
12 Nov 2020

AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

AM-Pharma B.V., an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, today announced that it has enrolled the first patient in its global Phase III trial named REVIVAL.
Galecto Announces Pricing of Initial Public Offering<
12 Nov 2020

Galecto Announces Pricing of Initial Public Offering

The shares are expected to begin trading on the Nasdaq Global Market on October 29, 2020 under the ticker symbol “GLTO
30 Oct 2020

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

Minoryx Therapeutics today announces that the European Investment Bank (EIB) has approved a €25 million financing.
29 Oct 2020

SparingVision Strengthens Management Team

SparingVision today announces the strengthening of its senior management team with the appointment of Dr. Florence Lorget as Chief Development Sciences Officer (“CDSO”) and Dr. Rajiv Gangurde as Chief Technology Officer (“CTO”).
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease<
27 Oct 2020

Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

First Approved Prescription Therapy Specifically for Short-Term Treatment of Dry Eye Disease
SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer<
21 Oct 2020

SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer

Ysios Capital joins SparingVison 44.5M€ financing round.
12 Oct 2020

Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020

Sanifit announced that it will present new data on its lead asset SNF472 at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting on October 22, 2020.
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline<
28 Sep 2020

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Ysios Capital joins Galecto 66M USD financing round.
24 Sep 2020

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Sperogenix Therapeutics and Minoryx Therapeutics announce that they have entered into an exclusive license agreement for the development and commercialization of leriglitazone.
LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs<
18 Sep 2020

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

Ysios Capital joins LAVA Therapeutics 83MUSD financing

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка